Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Probable Valid Biomarker	NCIT_C68765
Valid Biomarker	NCIT_C68763
Amlodipine Besylate/Benazepril Hydrochloride	NCIT_C29168	[Having a substantial blood pressure lowering capability, Amlodipine Besylate Benazepril Hydrochloride contains a dihydropyridine calcium blocker (amlodipine) and an angiotensin-converting enzyme (ACE) inhibitor (benazepril). A long-acting calcium channel antagonist, Amlodipine inhibits transmembrane calcium influx into vascular smooth muscle. Blocking ACE, Benazepril decreases vasopressive plasma angiotensin II. (NCI04)]
Oligodendroglial Component Present	NCIT_C68766	[A tumor component characterized by the presence of a diffuse, homogeneous population of tumor cells (oligodendroglial cells) with round nuclei and clear cytoplasm. The infiltrate has a honeycomb appearance. An oligodendroglial component can be seen in central nervous system tumors including glioblastomas and mixed gliomas.]
Skin Care Product	NCIT_C29169	[Any skin care product containing humectants, emollients and emulsifiers with moisturizing activity. These products increase the skin's hydration and are used to soften and protect dry skin.]
Acclimatization	NCIT_C68767	[The physiological process through which an organism grows accustomed to a new environment.]
Contamination	NCIT_C68768	[The presence of any substance or organism that makes a preparation impure.]
Decontamination	NCIT_C68769	[To rid of contamination.]
Preoperative Chemotherapy	NCIT_C68770	[The use of a chemotherapy agent that is administered to a patient prior to the surgical removal of a tumor.]
Clinical Endpoint	NCIT_C68771	[A characteristic or variable that reflects how a patient feels, functions, or survives. Clinical endpoints are distinct measurements or analyses of disease characteristics observed in a study or a clinical trial that reflect the effect of a therapeutic intervention. Clinical endpoints are the most credible characteristics used in the assessment of the benefits and risks of a therapeutic intervention in randomized clinical trials.]
End Point	NCIT_C25212	[A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.]
TP53 NM_000546.5:c.743G>A	NCIT_C146901	[A nucleotide substitution at position 743 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.]
TP53 NP_000537.3:p.R248Q	NCIT_C146903	[A change in the amino acid residue at position 248 in the cellular tumor antigen p53 protein where arginine has been replaced by glutamine.]
Surrogate Endpoint	NCIT_C68772	[A biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. The term surrogate endpoint applies primarily to endpoints in therapeutic intervention trials; however, it may sometimes apply in natural history or epidemiologic studies. The use of biomarkers as surrogate endpoints in a clinical trial requires the specification of the clinical endpoints that are being substituted, class of therapeutic intervention being applied, and characteristics of population and disease state in which the substitution is being made.]
TP53 NM_000546.5:c.743_744delGGinsAA	NCIT_C146902	[A complex substitution where the nucleotide sequence at positions 743 and 744 of the coding sequence of the TP53 gene has changed from guanine-guanine to adenine-adenine.]
Surrogate Endpoint Validation	NCIT_C68773
Inoculation	NCIT_C68774	[To implant microbes or infective materials, introduce immune serum, vaccines of various kinds, and other antigenic materials for preventive, curative, or experimental purposes.]
TP53 NM_000546.5:c.742C>T	NCIT_C146904	[A nucleotide substitution at position 742 of the coding sequence of the TP53 gene where cytosine has been mutated to thymine.]
Irradiation	NCIT_C68775	[Treatment with radiation, generally meaning exposure to ionizing radiation or radiation of wavelengths shorter than those of visible light.]
Adverse Event Seriousness Date	NCIT_C93720	[The date (and time) on which the seriousness code was assigned to the adverse event.]